145 related articles for article (PubMed ID: 19507339)
1. [The role of changes of matrix metalloproteinase in cardiovascular diseases].
Gasanov AG; Bershova TV
Biomed Khim; 2009; 55(2):155-68. PubMed ID: 19507339
[TBL] [Abstract][Full Text] [Related]
2. Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling.
Manso AM; Elsherif L; Kang SM; Ross RS
Cardiovasc Res; 2006 Feb; 69(3):574-84. PubMed ID: 16253214
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
[TBL] [Abstract][Full Text] [Related]
4. Cardiac remodeling and failure From molecules to man (Part II).
Fedak PW; Verma S; Weisel RD; Li RK
Cardiovasc Pathol; 2005; 14(2):49-60. PubMed ID: 15780796
[TBL] [Abstract][Full Text] [Related]
5. Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy.
Herpel E; Pritsch M; Koch A; Dengler TJ; Schirmacher P; Schnabel PA
Histopathology; 2006 May; 48(6):736-47. PubMed ID: 16681691
[TBL] [Abstract][Full Text] [Related]
6. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload.
Janicki JS; Brower GL; Gardner JD; Forman MF; Stewart JA; Murray DB; Chancey AL
Cardiovasc Res; 2006 Feb; 69(3):657-65. PubMed ID: 16376324
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
[TBL] [Abstract][Full Text] [Related]
8. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern.
Bruggink AH; van Oosterhout MF; de Jonge N; Ivangh B; van Kuik J; Voorbij RH; Cleutjens JP; Gmelig-Meyling FH; de Weger RA
J Heart Lung Transplant; 2006 Sep; 25(9):1091-8. PubMed ID: 16962471
[TBL] [Abstract][Full Text] [Related]
9. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
10. The role of matrix metalloproteinases in the pathogenesis of abdominal wall hernias.
Antoniou SA; Antoniou GA; Granderath FA; Simopoulos C
Eur J Clin Invest; 2009 Nov; 39(11):953-9. PubMed ID: 19656168
[TBL] [Abstract][Full Text] [Related]
11. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats.
Hu YB; Li DG; Lu HM
J Gene Med; 2007 Mar; 9(3):217-29. PubMed ID: 17351970
[TBL] [Abstract][Full Text] [Related]
12. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.
Martos R; Baugh J; Ledwidge M; O'Loughlin C; Conlon C; Patle A; Donnelly SC; McDonald K
Circulation; 2007 Feb; 115(7):888-95. PubMed ID: 17283265
[TBL] [Abstract][Full Text] [Related]
13. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation.
Xu J; Cui G; Esmailian F; Plunkett M; Marelli D; Ardehali A; Odim J; Laks H; Sen L
Circulation; 2004 Jan; 109(3):363-8. PubMed ID: 14732752
[TBL] [Abstract][Full Text] [Related]
14. Myocardial proteases and matrix remodeling in inflammatory heart disease.
Rutschow S; Li J; Schultheiss HP; Pauschinger M
Cardiovasc Res; 2006 Feb; 69(3):646-56. PubMed ID: 16417902
[TBL] [Abstract][Full Text] [Related]
15. Effects of interleukin-1 receptor antagonist on collagen and matrix metalloproteinases in stress-shielded achilles tendons of rats.
Ma Y; Yan X; Zhao H; Wang W
Orthopedics; 2012 Aug; 35(8):e1238-44. PubMed ID: 22868612
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
[TBL] [Abstract][Full Text] [Related]
18. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model.
Karagiannis ED; Popel AS
J Theor Biol; 2006 Jan; 238(1):124-45. PubMed ID: 16005020
[TBL] [Abstract][Full Text] [Related]
19. Cutis laxa: analysis of metalloproteinases and extracellular matrix expression by immunohistochemistry and histochemistry.
Gu W; Liu W; Yang X; Yuan X; Tian Y; Meng R; Zhao Q
Eur J Dermatol; 2011; 21(5):717-21. PubMed ID: 21719403
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
